Showing results (301-310 of 531) with videos related to

Sort By:
Pageof 54
Plos Medicine|October 19, 2007
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaborationJan P Vandenbroucke, Erik von Elm, Douglas G Altman, et al.
Journal of the American College of Cardiology|March 19, 2021
Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-ReducedJoão Pedro Ferreira, Faiez Zannad, Stuart J Pocock, et al.
Circulation|October 9, 2012
Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizationsJennifer K Rogers, John J V McMurray, Stuart J Pocock, et al.
European Journal of Heart Failure|June 27, 2023
Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: A subgroups analysis from the EMPHASIS-HF trialLuca Monzo, Nicolas Girerd, Kevin Duarte, et al.
Gaceta Sanitaria|March 3, 2009
[Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration]Jan P Vandenbroucke, Erik Von Elm, Douglas G Altman, et al.
Lancet (London, England)|September 13, 2005
5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trialK A A Fox, P Poole-Wilson, T C Clayton, et al.
Annals of Internal Medicine|October 17, 2007
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaborationJan P Vandenbroucke, Erik von Elm, Douglas G Altman, et al.
Lancet (London, England)|June 9, 2009
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trialPhilip D Home, Stuart J Pocock, Henning Beck-Nielsen, et al.
Circulation. Heart Failure|June 15, 2021
Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF TrialJoão Pedro Ferreira, Zohra Lamiral, John J V McMurray, et al.
European Journal of Heart Failure|May 27, 2020
Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCATJoão Pedro Ferreira, Xavier Rossello, Stuart J Pocock, et al.
Pageof 54